Limit search to available items
Record 10 of 16
Previous Record Next Record
Book Cover

Title Current antipsychotics / Gerhard Gross, Mark A. Geyer, editors
Published Heidelberg ; New York : Springer, [2012]
Online access available from:
Springer eBooks    View Resource Record  


Description 1 online resource (x, 416 pages) : illustrations
Series Handbook of experimental pharmacology, 1865-0325 ; v. 212
Handbook of experimental pharmacology ; v. 212. 0171-2004
Contents The Dopamine Dysfunction in Schizophrenia Revisited: New Insights into Topography and Course / Rebecca Kuepper, Mette Skinbjerg and Anissa Abi-Dargham -- Role of Dopamine D2 Receptors for Antipsychotic Activity / Nathalie Ginovart and Shitij Kapur -- Dopamine Receptor Signaling and Current and Future Antipsychotic Drugs / Kevin N. Boyd and Richard B. Mailman -- Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics / Herbert Y. Meltzer -- Managing the Prodrome of Schizophrenia / W. Wolfgang Fleischhacker and Alexander M. Simma -- Metabolic Consequences of Antipsychotic Therapy: Preclinical and Clinical Perspectives on Diabetes, Diabetic Ketoacidosis, and Obesity / David J. Heal, Jane Gosden, Helen C. Jackson, Sharon C. Cheetham and Sharon L. Smith -- Medical Needs in the Treatment of Psychotic Disorders / F. Markus Leweke, Thorsten M. Odorfer and J. Malte Bumb -- Antipsychotics in the Treatment of Bipolar Disorder / Jaskaran Singh, Guang Chen and Carla M. Canuso -- The Pharmacogenetics of Antipsychotic Treatment / Gavin P. Reynolds -- Interactions and Monitoring of Antipsychotic Drugs / Christoph Hiemke and Bruno Pfuhlmann -- Delivery Systems and Dosing for Antipsychotics / Cara R. Rabin and Steven J. Siegel -- Imaging as Tool to Investigate Psychoses and Antipsychotics / Jan Booij and Thérèse van Amelsvoort -- Biomarkers for Antipsychotic Therapies / Emilio Merlo Pich, Gabriel Vargas and Enrico Domenici -- Behavioral Animal Models of Antipsychotic Drug Actions / Daria Peleg-Raibstein, Joram Feldon and Urs Meyer
Summary "Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics ... Our intention was to capture both the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We [prepared] two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume."--Publisher's description
Related To Companion volume: Novel antischizophrenia treatments. Heidelberg ; New York : Springer, ©2012 9783642257582
Bibliography Includes bibliographical references and index
Notes Print version record and online resource; title from PDF title page (SpringerLink, viewed Sept. 24, 2013)
Subject Antipsychotic drugs.
Antipsychotic Agents -- therapeutic use.
Antipsychotic Agents -- antagonists & inhibitors.
Psychotic Disorders -- drug therapy.
Form Electronic book
Author Gross, Gerhard, active 2012, editor
Geyer, Mark A., editor
LC no. 2012952465
ISBN 9783642257612 (electronic bk.)
3642257615 (electronic bk.)